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Abstract
The Aristaless-related homeobox (ARX) gene is implicated in intellectual dis-
ability with the most frequent pathogenic mutations leading to expansions of
the first two polyalanine tracts. Here, we describe analysis of the ARX gene out-
lining the approaches in the Australian and Portuguese setting, using an inte-
grated clinical and molecular strategy. We report variants in the ARX gene
detected in 19 patients belonging to 17 families. Seven pathogenic variants,
being expansion mutations in both polyalanine tract 1 and tract 2, were
identifyed, including a novel mutation in polyalanine tract 1 that expands the
first tract to 20 alanines. This precise number of alanines is sufficient to cause
pathogenicity when expanded in polyalanine tract 2. Five cases presented a
probably non-pathogenic variant, including the novel HGVS: c.441_455del,
classified as unlikely disease causing, consistent with reports that suggest that in
frame deletions in polyalanine stretches of ARX rarely cause intellectual disabil-
ity. In addition, we identified five cases with a variant of unclear pathogenic
significance. Owing to the inconsistent ARX variants description, publications
were reviewed and ARX variant classifications were standardized and detailed
unambiguously according to recommendations of the Human Genome Varia-
tion Society. In the absence of a pathognomonic clinical feature, we propose
that molecular analysis of the ARX gene should be included in routine diagnos-
tic practice in individuals with either nonsyndromic or syndromic intellectual
disability. A definitive diagnosis of ARX-related disorders is crucial for an
adequate clinical follow-up and accurate genetic counseling of at-risk family
members.
ª 2015 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
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Introduction
Since its discovery in 2002, Aristaless-related homeobox
gene (ARX; MIM# 300382; GenBank: NM_139058.2) has
been implicated in X-linked intellectual disability (XLID)
(Bienvenu et al. 2002; Shoubridge et al. 2010). The ARX
gene, cytogenetically located on Xp21.3, encompasses
12.5 kb of genomic DNA and includes five coding exons
encoding a 562 amino acid protein. This gene is a paired-
type homeodomain transcription factor expressed predom-
inately in the fetal and adult brain, testis, skeletal muscle,
and pancreas. ARX has a critical role in brain development,
particularly in GABAergic interneuron migration during
cortical development (Miura et al. 1997; Kitamura et al.
2002; Stromme et al. 2002a). Hence, it is not surprising that
epilepsy and structural brain malformations including liss-
encephaly and agenesis of corpus callosum are frequently
observed in patients with ARX pathogenic mutations.
Although patients may present with intellectual disability
(ID) without additional clinical features (nonsyndromic
ID), the concomitant observation of neurological deficits,
with or without brain and/or genital anomalies suggests a
number of recognizable syndromes. The ARX-associated
spectrum of disorders includes Partington syndrome
(OMIM 309510) (Partington et al. 2004), Early Infantile
Epileptic Encephalopathy (OMIM 308350) (Kato et al.
2007), Agenesis of Corpus Callosum with Abnormal Geni-
talia (OMIM 300004) (Proud et al. 1992), and X-Linked
Lissencephaly with Ambiguous Genitalia (OMIM 300215)
(Kitamura et al. 2002). A genotype–phenotype relationship
exists and has recently been discussed (Shoubridge et al.
2010). Despite a broad range of phenotypes associated with
mutations in ARX, ID is a consistent clinical feature.
Although disease-causing variants occur across all five
coding exons, most are located in the largest exon, exon
2. These include expansion of the first or second polyala-
nine tracts. In particular, duplication of 24 base pairs
(bp), HGVS: c.441_464dup (referred to as dup24) in the
second polyalanine tract is by far the most common path-
ogenic mutation in this gene. As most mutations are in
this largest exon ARX mutation analysis is routinely con-
fined to screening exon 2.
Report of ARX mutations in the literature is hampered
by use of nonstandard nomenclature. Occasionally, publi-
cations describing “novel” sequence variants actually repre-
sent nomenclature errors, which are a cause of uncertainty
and misinterpretation especially in medical diagnostic set-
tings. For example, as many as seven descriptions can be
identified for a single ARX gene variant expanding the first
polyalanine tract (Stromme et al. 2002a; Wohlrab et al.
2005; Wallerstein et al. 2008; Kitamura et al. 2009; Fullston
et al. 2011; Mirzaa et al. 2013). There is an obvious need
for an effective molecular testing approach for ARX screen-
ing of ID patients and an unambiguous nomenclature for
description of ARX variants. In this report, we have under-
taken molecular analysis of the ARX gene using Portuguese
and Australian cohorts of patients with syndromic and
nonsyndromic ID. The continued characterization of ARX
variants not only contributes to the identification of
specific phenotypic features but also assists in unraveling
the pathogenicity of additional rare variants. This type of
information is required for accurate genetic counseling of
ARX at-risk family members.
Materials and Methods
Patient recruitment
Clinical data and blood samples were collected after
informed consent from the patients or their legal guard-
ians. The National Committee for Data Protection autho-
rized laboratory records. Relevant human research ethics
committees have approved these studies. A total of 138
patients from two cohorts were enrolled for this study.
Cohort 1 consisted of 101 Australian patients. Ninety
patients were directly referred for polyalanine tract 1
(pA1) and tract 2 (pA2) ARX size-variant analysis. Thir-
teen patients were referred for sequencing of the entire
open reading frame of ARX gene, including two cases that
had already been tested negative for size variants in pA1
and pA2, but were included to rule out mutations else-
where in the gene. Cohort 2 consisted of thirty-seven Por-
tuguese patients. Twenty-four patients were referred for
pA1 and pA2 ARX size-variant analysis. The remaining 13
patients were pulled out from a previous study consisting
of the simultaneous analyses of fragile-X (FMR1), FRAXE
(AFF2), and ARX (henceforward named multiplex screen-
ing) (Jorge et al. 2013). The selection of all subjects was
based on clinical criteria assessed by the patients’ geneti-
cist or neurologist. Seventeen patients were subsequently
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sequenced for the entire open reading frame of ARX gene,
based on clinical criteria (e.g. brain malformation)
assessed by patient physicians. Consanguinity was
excluded in the parents unless otherwise stated.
Molecular analysis
Cohort 1 – A PCR-based approach was used to screen for
expansions in pA1 and pA2 in exon 2 of ARX. Any changes
in migration of the amplicons detected by gel electrophore-
sis were subsequently analyzed by bidirectional cycle
sequencing reactions. The PCR and electrophoresis condi-
tions have been described in detail previously (Tan et al.
2013). Sequencing reactions were performed using ABI Big
Dye Terminator chemistry version 3.1 and purified products
subjected to an automated capillary sequencing on ABI 3100
sequencer (Applied Biosystems, Foster City, CA, USA) and
analysis was aided by Seqscape V2.5 (Applied Biosystems).
In 13 patients the entire open reading frame was screened.
Each of the five exons of ARX was amplified by PCR using
primers designed to amplify coding and flanking noncoding
sequence (Table S1). The exception to this is exon 2,
for which four overlapping amplicons were used to achieve
robust amplification of GC-rich regions coding for three
polyalanine tracts (Tan et al. 2013). Sequence of each ampli-
con was subsequently confirmed as outlined above.
Cohort 2 – A multiplex-PCR method designed to
amplify a portion of the second exon of ARX gene that
includes the first two of the three tracts of repetitive alanine
coding triplets was previously published by the authors
(Jorge et al. 2013). Further size estimation on capillary
electrophoresis allows identification of size variants: a
380 bp amplicon matches the expected normal-sized allele
and a 404 bp amplicon corresponds to the dup24. Any
changes in migration of the amplicons detected by gel elec-
trophoresis were subsequently analyzed by cycle sequencing
as described above for the Australian cohort. M13-tailored
primers were designed to amplify all exons and intron–
exon borders (Table S1) and sequencing of each of the five
ARX exons was done following standard procedures on
ABI 3130xl (Applied Biosystems, Foster City, CA, USA).
Bioinformatics
Human Genome Variation Society (HGVS) nomenclature
is stated for the ARX variants and refers to the GenBank
mRNA entry NM_139058.2 (den Dunnen and Antonara-
kis 2000). The software Mutalyzer 2.0.beta-31 (www.mut-
alyzer.nl, HGVS nomenclature version 2.0) was used to
check nomenclature of variants identified in the Portu-
guese and Australian cohorts. In addition, ARX-Locus
Specific Database, LOVD (http://LOVD.nl/ARX; last
accessed on March 2014) (Fokkema et al. 2011) and
Human Gene Mutation Database, HGMD Professional
(last accessed on April 2014) databases were crosschecked.
Statistical analyses
A chi-square (v2) distribution test was performed, with a
significance level (P) of 0.05 and a confidence of 95%, to
verify differences between each cohort (cohort 1 Austra-
lian and cohort 2 Portuguese). Descriptive data are pre-
sented as median with interquartile range (IQR).
Results
Clinical summary of patients referred for
diagnostic ARX study
Detailed clinical description and screening outcomes for
family A to Q is described in Data S1. All 138 patients
enrolled for ARX study had ID, with 127 (92.0%) being
male and 11 (8.0%) female (Table 1). Forty-two patients
(30.4%) were referred exclusively due to ID. Approxi-
mately half of the patients were also affected by a move-
ment disorder or epilepsy (67/138; 48.5%). A smaller
proportion of patients presented with behavior abnormal-
ities (17/138; 12%) or with brain malformations, with
and without genital malformations (12/138; 8.6%). Inter-
estingly, the cohorts differ in regards to the presence of a
movement disorder or epilepsy (P < 0.007) and brain
malformations, with and without genital malformations
(P < 0.001) (Cohort 2 mainly without specific ARX-
related referral). In total, 19 patients, four of whom are
female, belonging to 17 families, had an ARX sequence
change. Sequence variants were restricted to the polyala-
nine coding regions in ARX exon 2 and positioned in
pA1 (n = 6) and pA2 (n = 13) and therefore all variants
alter the ARX polyalanine content. Examples of partial
electropherograms of ARX variants identified are shown
in Figure S1. Inheritance was determined in eight male
patients (maternal) and one female (paternal). In one
male patient, a de novo variant was identified (one of six
for which gDNA from the parents was available; 16.7%).
Standardization of nomenclature for the
mutations in the polyalanine tracts of ARX
Publications were reviewed and ARX variants descriptions
were standardized and detailed unambiguously according
to recommendations of the HGVS (Table 2). The HGVS
recommends that duplications be designated by “dup” after
an indication of the first and last nucleotide(s) duplicated.
Moreover, the recommendations state that for all descrip-
tions the most 30 position possible is arbitrarily assigned to
have been changed. This does not concur with what has
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been previously annotated for these mutations. For exam-
ple, the most common mutation, c.429_452dup(24),
should be annotated as c.441_464dup according to the
HGVS. Given the sequence of this region we can see that
the 24 bp that are duplicated (as identified from sequenc-
ing affected patients) can either be lined up from the posi-
tion c.429 or c.441 as the most 30 position. A similar 30 shift
in nomenclature is also observed when the longer 27 bp
duplication (Demos et al. 2009) and the 33 bp duplication
(Reish et al. 2009) in this pA2 tract are considered (Fig.
S2).
The recurrent pA1 expansion previously described as
c.304insGCG is a duplicating insertion and should therefore
be considered a duplication, and according to the 30 rule,
must be described as c.306GGC[11] or c.315_335dup. Con-
cerning the identified pA1 deletion, there are two alterna-
tive descriptions: c.306GGC[6] and c.324_335del. If the
repeat was not sequenced but instead the size was deduced
from the length of a PCR fragment or while describing a
predicted (not analyzed) protein change, curved brackets
were used: p.(Ala151_Ala155del).
Clinical and molecular data of patients with
an ARX variant
The clinical and molecular data for each of the 17 patients
we are reporting with an ARX variant are detailed individu-
ally in Data S1 and summarized in Table 3, including the
age and reason for referral. Of the17 cases or variants identi-
fied, seven of these are known to be pathogenic, a detection
rate of 5%. In cohort 1 there were two pathogenic mutations
identified; (i) expansion of pA2 in Family G detected from
the 93 patients referred and screened by ARX size-variation,
and (ii) expansion of pA1 in Family A identified from the 13
patients referred and screened for sequencing of the entire
open reading frame of ARX gene. In cohort 2, there were six
males and one female from five families (Family H to L)
identified with pathogenic expansions in pA2 from the 13
patients from the previous multiplex screening study.
Polyalanine tract 1 variants
We identified six distinct families with a pA1 variant (Fam-
ilies A to F) (Table 4). The pathogenic c.306GGC[17],
p.(115Ala7) mutation in Family A leading to an increase in
pA1 to 23 alanines was identified in a patient with infantile
epileptic-dyskinetic encephalopathy. This variant has been
reported previously and is not found in the control popula-
tion (Stromme et al. 2002a; Poirier et al. 2006; Guerrini
et al. 2007; Fullston et al. 2011). Table 4 compares the clin-
ical features of this case with other patients identified with
this expansion. Overall, data in Table 4 is compiled from
27 affected individuals and includes 8 de novo cases (Guer-
rini et al. 2007; Poirier et al. 2008; Shinozaki et al. 2008;
Wallerstein et al. 2008; Absoud et al. 2009; Mirzaa et al.
2013), three cases of brother pairs (Guerrini et al. 2007;
Cossee et al. 2011) two cases of families with maternal
uncle–nephew pairs, one case of a pair of brothers and a
maternal male cousin (Bruyere et al. 1999; Stromme et al.
2002a), and four cases without a family history (Mirzaa
et al. 2013). There is only limited reporting of affected
females in these families. The family in Cossee et al. (2011)
lists a sister of the proband, with mild ID and epilepsy but
no indication of age of onset or the type of seizure or
movement disorder.
Variants in Families B, C, D, E, and F are classified as
variants of uncertain clinical significance (VUS). There are
reports of triplet expansions increasing the pA1 tract by
one, two, and three residues (Bienvenu et al. 2002; Grons-
kov et al. 2004; Oegema et al. 2012). The pathogenicity of
these shorter expansions is not well established. In this
study, there are four cases of diminishing size of duplicat-
ing/insertion GGC triplet repeats, with a novel four GCG
triplet repeat: c.306GGC[14], leading to a pA1 tract of 20
alanines, one case of a three GGC triplet repeat: c.306GGC
[13], and two cases of a single addition of a GCG triplet
repeat: c.306GGC[10];[11] and: c.306GGC[11]. The last
case describes a 12 bp deletion: c.306GGC[6] leading to a
shorter pA1 tract of 12 alanines.
Table 1. Clinical data of patients referred for diagnostic ARX study.
Cohort 1 (N = 101)
[13 sequenced]
Cohort 2 (N = 37)
[17 sequenced] Total (%)
Males: N; Age at diagnosis (years) (median; IQR) 93; (5.5; 9.1) 34; (11; 7) 127 (92)
Females: N; Age at diagnosis (years) (median; IQR) 8; (3.65; 38.15) 3; (8; 7.5) 11 (8)
Family history consistent with X-linked inheritance pattern: N 13 3 16 (11)
Nonsyndromic ID: N (%) 29 (28.7) 13 (35) 42 (30.4)
Syndromic ID: N (%)
With brain only or brain and genital malformations 4 (4) 8 (21) 12 (8.6)
With movement disorders and/or seizures (without
information on brain or genital malformations)
56 (55.4) 11 (30) 67 (48.5)
With behavior abnormalities 12 (11.9) 5 (14) 17 (12.3)
ADHD, attention deficit hyperactivity disorder; ID, intellectual disability; IQR, interquartile range.
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Polyalanine tract 2 variants
The most prevalent ARX mutation, a 24 bp duplication in
exon 2 leading to expansion of pA2 to 20 alanines,
c.441_464dup (herein named as dup24), was identified in
eight patients, including one female, belonging to six distinct
families (Families G to L) (Table S2). Interestingly, in the
two brothers of Family H a recognizable episodic dystonic
movement of the hands was identified in a retrospective
revaluation (at 16 and 11 years old) allowing the diagnosis
of the Partington-like syndrome (Fig. S3). Variants that are
unlikely to be, or are certainly not pathogenic were identified
in the remaining families with a pA2 variant (Families M to
Q) (as shown in Table 3). In cases of families M to P the
same nucleotide region within pA2 was deleted. This dele-
tion is classified as a variant that is unlikely to negatively
influence ARX function. In Family Q we report a novel pA2
deletion of 15 base pairs, c.441_455del;[=] resulting in a
contraction of five alanines in tract pA2 of ARX. Segregation
studies in this family revealed that two healthy male relatives
inherit the same variant. Analyses of 200 control chromo-
somes of healthy Portuguese controls did not detect this
novel variant indicating that this contraction represents a
very rare, benign polymorphism, and is not pathogenic.
Table 3. Summary of available clinical and molecular data of patients with an ARX variant.
Family Variant nomenclature
Change
in ala Age1 Primary referral reason/index case
Number of
cases and
gender Heredity Pathogenicity
pA1
A c.306GGC[17]/c.306_308[17] 16>23 2 months Developmental delay and infantile
seizures
1M Maternal Pathogenic
B c.306GGC[14]/c.306_308[14] 16>20 2 Developmental delay,
microcephaly, spasticity, and
dystonia
1M Maternal VUS
C c.306GGC[13]/c.306_308[13] 16>19 4 Developmental delay, intellectual,
and speech delay
1M Unknown VUS
D c.306GGC[10];[11] 16>17 4 Developmental delay and autistic
behavior
1F Unknown VUS
E c.306GGC[11]/c.306_308[11] 16>17 4 Mild developmental delay,
attention deficit, and
hyperactivity
1M Unknown
F c.306GGC[6]/c.324_335del 16<12 10 Intellectual disability 1M Unknown VUS
pA2
G c.441_464dup 12>20 6 months Developmental delay, spasms 1M Maternal Pathogenic
H 12>20 2; 7 Intellectual disability and
congenital macrocephaly (in
both)
2M3 Maternal
I 12>20 4; 39 Hyperactivity and developmental
delay; Dysmorphisms and
dystonia of the hands
2M4 Maternal
J 12>20 8 Intellectual disability, nonspecific
cranio-facial dysmorphisms
1M De novo
K 12>20 5 Motor impairment, severe speech
delay, and hyperactivity
1M Maternal
L c.441_464dup;[=] 12>20 10 Intellectual diability and speech
delay
1F (heterozygote) Unknown
M 12<4 4 Developmental delay 1M Unknown Unlikely
N c. 441_464del 12<4 13 Learning disability 1M Unknown Unlikely
O 12<4 8 Learning disability, attention
deficit, and hyperactivity
1M Maternal Unlikely
P c.441_464del;[=] 12<4 11 Intellectual disability 1F Unknown Unlikely
Q c. 441_455del;[=] 12<7 6 months Developmental delay, nonspecific
craniofacial dysmorphisms
1F Paternal Not
pathogenic2
VUS, variant of uncertain/unclassified significance; F, Female; M, Male.
1In years unless otherwise specified.
2Polymorphism absent in 200 control samples.
3Brothers.
4Nephew/uncle.
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Discussion
Molecular analysis of ARX identified sequence variants in
17 families. There were seven families harboring disease-
causing mutations, four families had unlikely pathogenic
variants and in the remaining five families a variant of
unclear/unclassified pathogenic significance (VUS) was
identified, including one novel variant. Expansions of the
first two polyalanine tracts in ARX account for more than
half (56%) of all mutations previously reported in this
gene (Shoubridge et al. 2010). Our strategy in the main
(127/138 patients) was based on screening exon 2 by size-
Table 4. Clinical features of patients with an ARX mutation leading to expansion of polyalanine tract 1 to 23 alanines
Clinical data
Previous studies (frequency) families
(27 males)#
This study family
A (male, 2.5 years) Total % (frequency)
DD/ID 100% (27/27) + 100% (28/28)
Age at diagnosis (median, IQR) Onset 0–7 (median 3; range 2.25 m)
(data from 9/27)
8 weeks Onset 0–7 (median 2;
range 2 m) (data from
10/28)
Formal development evaluation (IQ,
median age of evaluation in years)
1/27 mild, 15/27 severe, 2/27 Profound,
DD (median 3 Y)
Profound DD 1/28 mild, 15/28 severe,
3/28 Profound (median
2.5 Y)
DD onset prior to seizure onset (age at
diagnosis)
22% (6/27) (median age 2 m) + 25% (7/28)
Developmental regression with seizure
onset
22% (6/27) + 25% (7/28)
Evaluation of MRI Data for 14/27 patients Data for 15/28 patients
MRI abnormalities
Basal ganglia2 (age at diagnosis) 14% (2/14) (median age 5.5 Y) 13% (2/15)
Lateral ventricles3 (age at diagnosis) 21% (3/14) (median age 5 Y) 20% (3/15)
Brain atrophy (age at diagnosis) 21% (3/14) (median age 7 m) 20% (3/15)
Delayed myelination (age at diagnosis) 7% (1/14) (4 m) 7% (1/15)
No abnormalities (age at MRI) 50% (7/14) (age not supplied) 5 m – Neuroimage normal 53% (8/15)
Epilepsy 100% (27/27) + 100% (28/28)
Age at diagnosis (median, IQR) Median 3.75 m (Onset 0–18 m:2 m) 4 m Median 4 m
Initial phenotype
IS (age at diagnosis) 85% (23/27) (median 4, 1.95; m) + 85% (24/28)
Ohtahara (age at diagnosis) 4% (1/27) 4% (1/28)
Other – tonic clonic (age at diagnosis) 15% (4/27) (median 4.5, 8; m) 14% (4/28)
Later phenotype(s) No ongoing seizures at 2.5Y
Focal seizures 7% (2/27) 7% (2/28)
Myoclonic jerks (age at diagnosis) 15% (4/27) (median 2.5, 3.25 Y) 14% (4/28)
Tonic spasms, tonic clonic, and frontal
lobe epilepsy (age at diagnosis)
22% (6/27) (median 4, 3.3 Y) 21% (6/28)
Treatments reported to be of benefit ACTH, vigabatrin, phenytonin,
phentobarbitol, felbamate, zonisamide,
sodium valporate
Topiramate
Movement disorders 93% (25/27)* + 93% (26/28)
Age at diagnosis (median, IQR) 15/27 reported age of onset 2 to
11 months (5 m, 1.5 m)
7 m
Type (age at diagnosis often not reported)
Dystonia 52% (13/25) + (report details in the text) 53% (14/26)
Chorea 28% (7/25) + 30% (8/26)
Dysphagia 4% (1/25) 4% (1/26)
Episodes of status dystonicus 12% (3/25) + 15% (4/26)
Abnormalities of tone 64% (16/25) 61% (16/26)
Hypotonia 88% (14/16) + 88% (15/17)
Spasticity 43% (7/16)  41% 7/17)
Family history Maternally inherited
2Basal ganglia: cavitated, fragmented, indistinct, small, or normal (Kato et al, 2004).
3Lateral ventricles: mildly to moderately enlarged lateral ventricles, sometimes in continuity with an interhemispheric fluid space (Kato et al, 2004).
*Remaining two patients are deceased and complete clinical assessments were not undertaken or reported.
# 8 de novo cases.
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variant analysis (PCR and gel electrophoresis or multiplex
analysis) followed by sequence analysis where indicated.
Thirty of the 138 patients underwent sequencing of the
entire ARX coding regions, many after a negative out-
come by size-variant analysis. Of the 8 variants identified,
5 ARX variants were detected using multiplex screening
that enables the simultaneous investigation of FMR1,
AFF2, and ARX genes (Jorge et al. 2013) and three ARX
variants were detected by direct sequencing of the gene.
Despite these different approaches, all ARX variants iden-
tified in this study were located in exon 2 of the gene,
specifically in pA1 and pA2. In our previous study, of
the eight pathogenic variants identified only three were
outside the pA tracts in a cohort of 613 mostly isolated
cases, 500 of which had the entire open reading frame
sequenced (Fullston et al. 2011). Hence, we predict the
likelihood of missing a mutation elsewhere in the gene in
the patients screened only by size-variant analysis would
be quite low. From 138 patients we identified 7 known
pathogenic variants, an overall detection rate of 5%. It
remains challenging to assess the true prevalence of ARX
mutations given the potential ascertainment bias. Here,
we report a small number of mostly isolated cases and
some brother pairs with a rate higher than the 1.3–1.5%
from isolated cases (de Brouwer et al. 2007; Fullston et al.
2011), and 2.2% from brother pairs (Poirier et al. 2006)
but substantially less than the 9.5% reported when screen-
ing large XLID families (Poirier et al. 2006).
ARX polyalanine tract expansion mutations of the same
size and composition can cause a range of overlapping, but
distinct clinical phenotypes (Fig. 1). Each reported case is
depicted as a single circle on the graph against the length of
the tract involved. Some circles represent a single individ-
ual, whereas others represent multiple affected individuals
within a family. For familial cases, the prevailing phenotype
reported was used to designate the position on the axis of
Figure 1. This unusual breadth of variation in the clinical
presentations, intra and interfamilial variability, associated
with the frequent expansion mutations in pA1 and pA2 in
particular has been noticed, but not adequately explained
(Turner et al. 2002; Shoubridge et al. 2010). The clinical
features of each of these cases are summarized in Table 4
and Table S2, respectively.
The most frequent mutation in pA1 expands the 16 reside
tract to 23 alanines. To date there are 18 families reported
(across 27 individuals), increasing to 19 families (and 28
individuals) with our report of Family A. This particular
mutation is associated with severe clinical outcomes ranging
from generalized dystonia in the absence of infantile spasms
(Shinozaki et al. 2008), to the more common X-linked
infantile spasms (Stromme et al. 2002a; Wohlrab et al.
2005; Guerrini et al. 2007; Poirier et al. 2008; Cossee et al.
2011; Mirzaa et al. 2013), through to infantile epileptic-dys-
kinetic encephalopathy (Reish et al. 2009) and Ohtahara
syndrome (Demos et al. 2009) (Table 4). The age of onset
and severity of the phenotype also varies; with reports of
rapid neurodegeneration and death within the first year of
life (Absoud et al. 2009). An added complexity is the over-
lapping clinical spectrum with mutations in other regions of
ARX, with a number of patients reported with the severe
early infantile encephalopathy of Ohtahara syndrome due
to mutations outside of expansions to pA1 and pA2. These
mutations include early truncating mutations (suggested to
re-initiate translation at a subsequent methionine) (Fullston
et al. 2009) and missense and nonsense mutations in the Ar-
istaless domain (Giordano et al. 2010; Kato et al. 2010; Ek-
sioglu et al. 2011; Sartori et al. 2011; Bettella et al. 2012).
This highlights the need for detailed case reports of patients
with expanded polyalanine tract mutations (and other
mutations) in ARX to better identify the key clinical features
associated with these infantile spasms.
The most frequent pA2 mutation expands the 12 reside
tract to 20 alanines. To date there are 46 cases/families
reported with this mutation, increasing to 52 cases with
our report of Families G to L. Clinical outcomes always
include mild to moderate ID either as the only consistent
clinical feature, or in association with dystonia, particularly
of the hands known as Partington syndrome, though to
infantile spasms or West syndrome (Shoubridge et al.
2014). No syndromic features were recognized at the first
referral in 13 of 17 patients, identified with ARX mutations.
A retrospective detailed evaluation of some cases with the
dup24 mutation revealed features of an “ARX-syndrome.”
Cognitive profile evaluation in three patients with ID, and
subsequent clinical assessment of a maternal male relative
also with ID, enabled identification of hand dystonia in
each male patient. Thus, identification of the dup24 patho-
genic mutation was essential for the diagnosis of Partington
syndrome and for appropriate genetic counseling.
In addition to the well-established pathogenic expan-
sions to both tracts there are several examples of triplet
expansions increasing the pA1 tract by one, two, and three
residues (Bienvenu et al. 2002; Gronskov et al. 2004; Oeg-
ema et al. 2012). The pathogenicity of these shorter expan-
sions is not well established. In this study, we identified
triplet repeat expansion increasing pA1 by one (Family D
and E), three (Family C), and a novel 4 residues (Family
B). In this last case, the novel mutation in pA1 expands the
first tract to 20 alanines. This precise number of alanines is
sufficient to cause pathogenicity when expanded in pA2.
Hence, it is difficult to predict the pathogenic impact of
this expansion in pA1. In the absence of functional studies
to determine the in vivo pathogenic status, haplotype
analysis, in-silico and population studies are of particular
importance. When we examine the genotype–phenotype
spectrum associated with all cases of expansions to pA1
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and pA2 of ARX we see that our patients generally cluster
quite well with previously reported patients with the same
mutations (Fig. 1). However, there are outliers that do not
fit with the genotype–phenotype correlation of a more
severe outcome with a longer length of expansion. The
novel mutation increasing the pA1 from 16 to 20 alanines
in Family B gives rise to a phenotype more severe than seen
in many patients with pA2 mutations increasing pA2 to 20
alanines in length. Although the authors have listed this
mutation as a variant of unknown significance, additional
cases may add weight to the potential pathogenicity of this
mutation. Differential diagnoses are being considered for
this patient. In the case of Family D, the variant was
reported in a female patient. The variant in pA1 was of
unknown significance, with the alanine tract increasing
from 16 to 17 alanines (Family D). The female proband in
Family D was also diagnosed with classic galactosemia,
which can explain a mild intellectual impairment even in
patients who avoid galactose. There is one other report of
this change (Gronskov et al. 2004). Pathogenicity should
not be ruled out in the variant c.331_333dupGCG, nor in
others that cause a small increase in alanine residues of pA1
with further evidence needed to clarify the pathogenicity of
small increases to alanine content in this tract.
There were three other cases in which females were iden-
tified with an ARX variant, this time in pA2 (Family L, P
and Q). The female in Family L heterozygote for dup24 was
lost to follow-up. The remaining two female cases had dele-
tions in pA2. Deletions in pA2 are difficult to interpret in
terms of pathogenicity (Shoubridge et al. 2010). The het-
erozygous c. 441_464del in one case from our cohort (Fam-
ily P) was considered as a causative mutation in a male
patient with nonsyndromic mental retardation previously
published (Troester et al. 2007). Troester et al. interpreted
the heterozygous deletion in the patient’s asymptomatic
mother and sister as a result of favorable X-inactivation in
the brain. Evidence from several other publications places
in frame deletions in exon 2, leading to retraction of pA1
and pA2, in an unlikely pathogenic group, based in part on
some of these deletions also being reported in healthy,
unaffected males (Bienvenu et al. 2002; Gronskov et al.
2004; Conti et al. 2010; Fullston et al. 2011). In agreement,
the c.44a_455del;[=] variant identified in the female pro-
band of Family Q was paternally inherited and did not seg-
Phenotype  severity 
Clinical  
Threshold 
Infanle Spasms 
 Threshold 
Severe  
Infanle Spasms (OS) 
Threshold 
 …….      17     18      19     20      21      22    23    24     25   26    27 
Total Number of Alanines per tract 
PolyA1    PolyA2 
16 12 
Published families 
Families in this report 
Figure 1. Clinical variability associated with expanded in polyalanine tract mutations in ARX. The panel below the graph shows the normal
length of the pA1 as 16 residues and pA2 as 12 residues. The graph shows the relationship between the number of alanines and the phenotype
severity in published families with pA1 (white circles) and pA2 families (black circles). Each circle represents a separate published case; some cases
being a single affected individual whereas other cases are comprised of multiple affected individuals within a family. The black circle with
horizontal line indicates a polyalanine tract expansion interspersed with a glycine residue (10A-G-12A) (Demos et al. 2009). The cases we are
reporting in this study are shown as hatched circles. The same mutation can lead to different clinical outcomes, whereas different mutations can
lead to consistent outcomes. With increasing length of residues in the pA tracts, the clinical presentation becomes more severe, with early onset
seizures being a frequent but not consistent finding. Modified with permission from (Shoubridge et al. 2014).
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regate with cognitive impairment in the family, suggesting
a nonpathogenic variant classification. The last case identi-
fied a previously unreported, presumed rare polymorphism
(HGVS: c.441_455del; [=]) of paternal origin was identified
in a heterozygous state in one family (Family Q).
Due to the overlap of phenotypic features in ARX-
related and Fragile-X syndromes and family history of X-
linked inheritance pattern, patients previously classified as
having a normal FMR1 profile by Southern blot irrespec-
tive of their phenotypic presentation were subsequently
screened for an ARX-related disorder (exon 2 size-vari-
ant). Clinical details given by the referring physicians
requesting screening for fragile-X syndrome often only
relates specifically to fragile-X diagnosis. Consequently, in
many cases there is little or no available clinical informa-
tion specifically referable to ARX-related phenotypes.
Given the outcomes of our screening strategy, we recom-
mend that all patients referred for fragile-X (after con-
firming a normal karyotype), particularly those with a
priori nonsyndromic ID or XLID, but also including cases
with isolated cognitive impairment, be routinely screened
for exon 2 size variants in ARX.
This study aims to establish standard nomenclature for
ARX sequence variation description based on the published
guidelines of the HGVS. One of the pitfalls in standardiza-
tion of description of genetic variants concerns the absence
of electropherogram visualization, hindering an effective
variant comparison. However, variable description of ARX
variants, combined with the low prevalence of familial cases
and in many cases a lack of functional studies, hampers the
establishment of pathogenicity and leads to confusion and
misinterpretation, particularly in medical diagnostic set-
tings. Hence, we have collated and compared the nomen-
clature of the variants to clarify this process and provide a
useful resource. We encourage clinical researchers and clin-
ical laboratory specialists to use Locus Specific Databases
(LSDBs) (such as LOVD for ARX gene) to continue the
process of collecting and describing identified sequence
variants (http://databases.lovd.nl/shared/variants/ARX).
This can ultimately be utilized to suggest and discuss accu-
rate variant terminology and ensure clarity of variant
descriptions essential for proper genetic counseling.
Conclusion
The screening of mutations in the exon 2 of the ARX gene,
followed by sequencing of the entire ARX gene, enabled the
diagnosis of ARX-related disorders in eight patients from
six families, presenting with different clinical phenotypes.
Mutations were described using standardized and consis-
tent nomenclature. In addition, several other pA1 expan-
sions including the novel mutation expanding the first pA
tract by four alanines in one family remain of unknown
clinical significance. Further studies are required to charac-
terize the impact of these variants on the functionality of
ARX. Molecular screening of ARX gene is frequent in
patients with XLID, ID presenting with infantile epilepsy
or movement disorder or brain and genital malformations.
Data from this and other studies led us to recommend that
molecular screening of exon 2 of the ARX gene be done in
all patients referred for fragile-X (after a normal karyo-
type), particularly those with apparent nonsyndromic ID
of unknown cause, or in which the “Partington” hand dys-
tonia is recognized.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Data S1. Supplementary note.
Figure S1. ARX mutations identified.
Figure S2. Differences in regions designated as duplicated
in pA2 expansion mutations of ARX. The sequence span-
ning c.421 and c.471 is shown encompassing pA2 of
ARX. The region duplicated is indicated for the existing
published nomenclature (underlined and in bold) as com-
pared to the HGVS nomenclature (dotted box) for the
24dup (top panel), 27 bp (middle panel), and the 33 bp
duplication (bottom panel).
Figure S3. Block design subtests of WISC-III (Wechsler
Scale), performed by the younger brother from Family H,
demonstrate his inability to make purposeful hand move-
ments due to lack of manipulative skills, thus suggesting
hand dystonia.
Table S1. PCR primers designed to amplify pA1 and pA2
or ARX ORFs.
Table S2. Clinical features of patients with an ARX muta-
tion leading to expansion of polyalanine tract 2 to 20 ala-
nines (dup 24).
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